Why the study?
Does allograft aortic valve replacement provide comparable durability and freedom from reoperation compared to porcine and pericardial bioprostheses in patients requiring AVR?
Does allograft aortic valve replacement provide comparable durability and freedom from reoperation compared to porcine and pericardial bioprostheses in patients requiring AVR?
Allografts for aortic valve replacement offer low rates of early valve-related events, but the risk of structural valve deterioration increases over time and is comparable to stented xenografts.
Answers are grounded in this paper and cite their sources.
Comparable reoperation risk to xenografts supports allograft consideration in AVR; extends observational durability data but leaves open need for randomized trials.
OBJECTIVE: Whether allografts are the biological valve of choice for AVR in non-elderly patients remains a topic of debate. In this light we analyzed our ongoing prospective allograft AVR cohort and compared allograft durability with other biological aortic valve substitutes. METHODS: Between April 1987 and October 2005, 336 patients underwent 346 allograft AVRs (95 subcoronary, 251 root replacement). Patient and perioperative characteristics, cumulative survival, freedom from reoperation, and valve-related events were analyzed. Using microsimulation, for adult patients, age-matched actual freedom from allograft reoperation was compared to porcine and pericardial bioprostheses. RESULTS: Mean age was 45 years (range 1 month to 83 years); 72% were males. Etiology was mainly endocarditis 32% (active 22%), congenital 31%, degenerative 9%, and aneurysm/dissection 12%. Twenty-seven percent underwent prior cardiac surgery. Hospital mortality was 5.5% (N=19). During follow-up (mean 7.4 years, maximum 18.5 years, 98% complete), 54 patients died; there were 57 valve-related reoperations (3 early technical, 11 non-structural, 39 structural valve deterioration (SVD), 4 endocarditis), 5 cerebrovascular accidents, 1 fatal bleeding, 8 endocarditis. Twelve-year cumulative survival was 71% (SE 3), freedom from reoperation for SVD 77% (SE 4); younger patient age was associated with increased SVD rates. Actual risk of allograft reoperation was comparable to porcine and pericardial bioprostheses in a simulated age-matched population. CONCLUSIONS: The use of allografts for AVR is associated with low occurrence rates of most valve-related events, but over time the risk of SVD increases, comparable to stented xenografts. It remains in our institute the preferred valve substitute only for patients with active aortic root endocarditis and for patients in whom anticoagulation should be avoided.
No takes yet. Share an insight, caveat, or question.
Takkenberg et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: